The phase II trial of non-squamous NSCLC, Be Study, suggested that the combination of atezolizumab and bevacizumab was a potential strategy for patients with PD-L1 positive and without EGFR/ALK/ROS1 alterations [53]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.